Comments
Glenmark Pharmaceuticals today said it has received tentative approval from the US health regulator for its generic version of Vimpat Oral Solution, used in treatment of epilepsy.
“Glenmark Pharmaceuticals Inc, USA, has been granted tentative approval by the US Food and Drug Administration (USFDA) for its Lacosamide Oral solution, 10 Mg/mL, the generic version of Vimpat Oral Solution, 10 Mg/mL of UCB, Inc,” it said in a BSE filing.
The company will market this product upon receiving final approval of Lacosamide Oral solution, 10 Mg/mL.
“The patent listed in the Orange Book for Vimpat Oral Solution, 10 Mg/mL is scheduled to expire on March 17, 2022,” it added.
According to IMS Health sales data for the 12 months to January 2016, Vimpat has annual sales of around $55.4 million, Glenmark said.
The company’s current portfolio consists of 108 products authorised for distribution in the US marketplace and 61 Abbreviated New Drug Applications (ANDA) pending approval with the USFDA.
Glenmark Pharmaceuticals shares were trading at Rs 787.20 in the morning deals on the BSE, down 2.95 per cent.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.